{"id":1667,"date":"2025-11-19T13:08:01","date_gmt":"2025-11-19T13:08:01","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T18:32:46","modified_gmt":"2026-06-26T18:32:46","slug":"amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/","title":{"rendered":"Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure"},"content":{"rendered":"\n<p><strong>Montreal, Quebec \u2013 November 19, 2025&nbsp;<\/strong>\u2013 Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the appointment of Amy Rudolph, PhD, to its Board of Directors. Dr. Rudolph brings more than 25 years of leadership experience in the global pharmaceutical industry, with deep expertise spanning discovery, clinical development, medical affairs, and market access.<\/p>\n\n\n\n<p>Dr. Rudolph currently serves as Head of Global Medical Affairs and Cross-TA Medical Affairs at Boehringer Ingelheim, where she leads a global transformation to build a market-leading Medical Affairs organization focused on external engagement, digital\/AI integration, evidence generation, advanced analytics, and learning.&nbsp;<\/p>\n\n\n\n<p>\u201cWe are thrilled to welcome Amy Rudolph to our Board of Directors,\u201d said Paul Truex, Chairman and CEO of Thryv Therapeutics. \u201cHer extensive experience in medical affairs, evidence generation, and cross-functional drug development will be invaluable as we progress our SGK1 inhibitor pipeline toward late-stage clinical studies.\u201d&nbsp;<\/p>\n\n\n\n<p>\u201cWe are also deeply grateful to Scott Weiner for his many contributions to the Board of Directors,\u201d added Truex. \u201cWe\u2019re pleased that he will remain closely involved with Thryv in an advisory capacity.\u201d&nbsp;<\/p>\n\n\n\n<p>Prior to joining Boehringer Ingelheim, Dr. Rudolph held leadership roles at Novartis Pharmaceutical Corporation, where she served as Head of HCS (Healthcare Systems) Partnerships in Global Drug Development and Head of Evidence and Launch Excellence in Global Medical Affairs. Earlier in her career, she held key positions at Pfizer Inc., where she was responsible for the atherosclerosis and stroke platforms, early development, and licensing\/technology evaluations, and began her scientific career with G.D. Searle\/Pharmacia\/Pfizer.&nbsp;<\/p>\n\n\n\n<p>Over the course of her career, Dr. Rudolph has played key roles in the development and launch of multiple cardiovascular therapies, including Inspra, Eliquis, Lipitor, Diovan, Diovan\/HCT, Exforge, Tekturna, and Entresto, as well as in the development of Serelaxin and Amturnide.&nbsp;<\/p>\n\n\n\n<p>Dr. Rudolph earned her Ph.D. in Biochemistry and Molecular Biology from Washington University in St. Louis and is an inventor on 13 patents and numerous scientific publications spanning preclinical research, drug development, and real-world evidence.&nbsp;<\/p>\n\n\n\n<p>\u201cI am honored to join Thryv Therapeutics\u2019 Board of Directors,\u201d said Amy Rudolph. \u201cThryv\u2019s science and patient-centered mission resonate deeply with me, and I look forward to supporting the company\u2019s continued progress in addressing serious cardiovascular conditions.\u201d&nbsp;<\/p>\n\n\n\n<p>Dr. Rudolph joins the Board of Directors as Scott Weiner, who has served as a valued member since 2021, transitions to an observer role. Mr. Weiner will remain on the Board of Directors of the company\u2019s subsidiary, Thryv Therapeutics USA, Inc., while also serving as an advisor to the company.&nbsp;<\/p>\n\n\n\n<p><strong>About Thryv\u2019s SGK1 Inhibitor Platform<\/strong>&nbsp;<\/p>\n\n\n\n<p>Thryv Therapeutics is advancing a portfolio of potent and selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitors that target the fundamental mechanisms driving electrical and structural remodeling in the heart. THRV-1268, the company\u2019s lead clinical candidate, is a best-in-class, highly selective SGK1 inhibitor with the potential to transform the treatment landscape for Long QT Syndrome (LQTS), heart failure (HF), and atrial fibrillation (AFib)\u2014three serious cardiac conditions with urgent unmet medical needs.&nbsp;<\/p>\n\n\n\n<p><strong>About Thryv Therapeutics&nbsp;Inc.<\/strong><\/p>\n\n\n\n<p>Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat genetic channelopathies, cardiometabolic diseases, and cardiomyopathies with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).&nbsp;&nbsp;For more information, please visit www.thryvtrx.com.&nbsp;<\/p>\n\n\n\n<p><strong>Media Inquiries<\/strong><\/p>\n\n\n\n<p><a href=\"mailto:brittany@thryvtrx.com\">brittany@thryvtrx.com<\/a>&nbsp;| 514 973 0915<\/p>\n\n\n\n<p><a href=\"https:\/\/thryvtrx.com\/news\/amy-rudolph-joins-bod\">Read the original press release here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Montreal, Quebec \u2013 November 19, 2025&nbsp;\u2013 Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1620,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"company":[18],"class_list":["post-1667","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-portfolio-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure | adMare\" \/>\n<meta property=\"og:description\" content=\"Montreal, Quebec \u2013 November 19, 2025&nbsp;\u2013 Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-19T13:08:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T18:32:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-eng-1-1758136916-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1199\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure\",\"datePublished\":\"2025-11-19T13:08:01+00:00\",\"dateModified\":\"2026-06-26T18:32:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/\"},\"wordCount\":608,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-eng-1-1758136916-1.png\",\"articleSection\":[\"Portfolio Companies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/\",\"name\":\"Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-eng-1-1758136916-1.png\",\"datePublished\":\"2025-11-19T13:08:01+00:00\",\"dateModified\":\"2026-06-26T18:32:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-eng-1-1758136916-1.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/thryv-therapeutics-eng-1-1758136916-1.png\",\"width\":1199,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure | adMare","og_description":"Montreal, Quebec \u2013 November 19, 2025&nbsp;\u2013 Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/","og_site_name":"adMare","article_published_time":"2025-11-19T13:08:01+00:00","article_modified_time":"2026-06-26T18:32:46+00:00","og_image":[{"width":1199,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-eng-1-1758136916-1.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure","datePublished":"2025-11-19T13:08:01+00:00","dateModified":"2026-06-26T18:32:46+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/"},"wordCount":608,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-eng-1-1758136916-1.png","articleSection":["Portfolio Companies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/","name":"Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-eng-1-1758136916-1.png","datePublished":"2025-11-19T13:08:01+00:00","dateModified":"2026-06-26T18:32:46+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-eng-1-1758136916-1.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/thryv-therapeutics-eng-1-1758136916-1.png","width":1199,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/amy-rudolph-phd-joins-thryv-therapeutics-board-of-directors-to-support-portfolio-progression-into-heart-failure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Amy Rudolph, PhD, Joins Thryv Therapeutics\u2019 Board of Directors to Support Portfolio Progression into Heart Failure"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=1667"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1667\/revisions"}],"predecessor-version":[{"id":1668,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1667\/revisions\/1668"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/1620"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=1667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=1667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=1667"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=1667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}